ARIAD (ARIA) Commences Phase I/II Study on Cancer Drug
ARIAD Pharmaceuticals, Inc. ARIA announced the commencement of a phase I/II study on AP32788, for the treatment of patients with non-small cell lung cancer (NSCLC) with specific mutations in EGFR or HER2. […]